Wednesday, December 21, 2011
Provectus Pharmaceuticals Inc., of Knoxville, Tenn., and its five wholly owned subsidiaries Provectus Biotech Inc., Provectus Devicetech Inc., Provectus Imaging Inc., Pure-ific Corp. and Xantech Pharmaceuticals Inc. raised an undisclosed amount of money in an unregistered offering. Each unit sold consisted of the right to receive one share of common stock in up to all five subsidiaries and a warrant to purchase three-fourths of one share of the company's common stock.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.